Markers of bone remodeling in neoplastic and bone-related lesions.
OBJECTIVE
The aim of this study was to investigate the expression of bone resorption (RANK/RANKL), bone resorption inhibitor (osteoprotererin [OPG]), and bone formation marker (osteocalcin [OC]) in neoplastic and bone-related lesions (BRL).


METHODS
Using immunohistochemistry, their expression was evaluated in ossifying fibroma (OF), fibrous dysplasia (FD), simple bone cysts (SBC), central giant cell lesions (CGCL), and osteosarcoma (OS).


RESULTS
Quantitative analyses of the expression of bone markers between all lesions, considering fibroblast-like cells and bone matrix, showed that RANK-RANKL presented higher expression in OF and CGCL, whereas OPG and OC presented higher expression in FD and SBC. There was higher expression of all proteins investigated when OS was the BRL. Moreover, the RANKL expression was greater than OPG in this neoplasm.


CONCLUSIONS
Our data indicate that the bone resorption markers are more highly expressed in OF, CGCL, and OS than in FD and SBC, indicating a significant association between these proteins and the clinical behavior of these lesions.
Elias
Larissa Santana Arantes
LS
Department of Stomatology (Oral Pathology), Dental School, Federal University of Goiás, Goiás, Brazil.
Costa
Rafael Ferreira
RF
Carvalho
Marco Aurélio
MA
Batista
Aline Carvalho
AC
Silva
Tarcília Aparecida
TA
Leles
Cláudio Rodrigues
CR
Mendonça
Elismauro Francisco
EF
D000293:Adolescent; D000328:Adult; D015415:Biomarkers / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis; D001857:Bone Matrix / Q000473:pathology; D016723:Bone Remodeling / Q000502:physiology*; D001862:Bone Resorption / Q000503:physiopathology; D002648:Child; D005260:Female; D005347:Fibroblasts / Q000473:pathology; D018214:Fibroma, Ossifying / Q000473:pathology; D005357:Fibrous Dysplasia of Bone / Q000473:pathology; D015726:Giant Cells / Q000473:pathology; D006101:Granuloma, Giant Cell / Q000473:pathology; D006801:Humans; D007570:Jaw Cysts / Q000473:pathology; D007571:Jaw Diseases / Q000473:pathology*; D007573:Jaw Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010006:Osteoblasts / Q000473:pathology; D015675:Osteocalcin / Q000032:analysis*; D010010:Osteoclasts / Q000473:pathology; D010012:Osteogenesis / Q000502:physiology; D053244:Osteoprotegerin / Q000032:analysis*; D012516:Osteosarcoma / Q000473:pathology; D053245:RANK Ligand / Q000032:analysis*; D053246:Receptor Activator of Nuclear Factor-kappa B / Q000032:analysis*; D017154:Stromal Cells / Q000473:pathology; D055815:Young Adult
D015415:Biomarkers; D014408:Biomarkers, Tumor; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; C505686:TNFRSF11A protein, human; C506030:TNFRSF11B protein, human; D015675:Osteocalcin